TECregen, a biotechnology company focused on thymus regeneration, has completed a CHF 10 million (EUR 10.7 million / USD 12.6 million) seed financing round and appointed Dr Bo Rode Hansen as chairman of its board of directors.

The seed financing was led by Boehringer Ingelheim Venture Fund (BIVF), with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, HighTech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. TECregen said the investment will support development of its thymopoietic biologics, which are designed to rejuvenate thymic epithelial cells, restore immune function, and strengthen overall immune resilience.

Dr Bo Rode Hansen brings over 20 years of leadership experience in the pharmaceutical and biotech sectors, including previous roles as CEO of Scandion Oncology A/S, founding president of Genevant Sciences, and senior leadership positions at Roche and Santaris Pharma. He will help guide TECregen’s strategic growth and advance its thymus regeneration programmes.

“I am honored to join TECregen’s Board at such a pivotal time for the company,” Hansen said. “The team’s pioneering work in thymus regeneration has the potential to redefine treatment approaches for immune ageing and related disease. I look forward to working with the management team and our investors to accelerate the development and delivery of these transformative therapies to patients who need them most.”

Filippo Oliveri, co-founder and board director of TECregen, added: “We welcome Bo as our new Chairman. His wealth of industry expertise and proven leadership will be invaluable as we pursue our mission. Backed with strong investor support, TECregen is well positioned to accelerate its thymus regeneration initiative and deliver innovative immune rejuvenation therapies to patients.”

Dr Philipp Müller, investment manager at BIVF, said: “TECregen’s innovative approach to thymus regeneration firmly positions the company at the forefront of targeted biologics designed to restore immune function, with a clear trajectory toward the clinic. The ability to modulate and restore thymic function paves the way for new therapeutic opportunities across immunology, oncology, and rare diseases. We are enthusiastic to support TECregen as it advances toward clinical development.”

TECregen said its thymus-targeted biologics have potential across multiple indications and that the company is preparing to advance its programmes toward clinical development.